Mucine isovorm-microbioom interacties die de ernst van COVID19 bepalen:een hulp bij de stratificatie van patiënten?

Project Details

Layman's description

Infection with SARS-CoV-2 mostly leads to a mild self-limiting
respiratory tract illness, however, some patients develop severe
progressive pneumonia, multiorgan failure, and death. This project
aims to determine factors that dictate the course of COVID19 beyond
cytokines. We have prior data that specific aberrantly expressed
mucins, triggered by SARS-CoV-2, regulate ACE2 expression and
affect lung barrier integrity. Such mucin alterations are clinically
relevant as excessive mucin production is seen in severe COVID-19
illness obstructing the respiratory tract and complicating recovery.
Here, we will first identify differentially expressed mucin isoforms in
COVID-19 patients exhibiting the entire spectrum of disease severity.
Thereafter, therapeutics currently used for COVID-19 will be
screened for their ability to reduce mucin abundance. As mucin
expression is also a critical factor in microbiome homeostasis and
dysbiosis might modulate COVID-19 severity, this project secondly
aims to map the microbiome associated with different degrees of
disease severity. Unravelling mucin isoform-microbiome interactions
that shape the course of SARS-CoV-2 infection will lead to the future
identification of those patients who are in danger of progressing to
severe disease. This project will also improve the choice for an
appropriate treatment as well as the time frame of treatment options
once infection occurs.
Effective start/end date1/11/2031/10/23


  • Research Fund - Flanders: €42,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.